The inaccuracy of a genetic test that gave false positives to patients has resulted in doctors calling for a crackdown on genetic testing. If a woman’s BCRA gene is faulty, her risk of breast and ovarian cancer is much higher than average. People with a family history of these cancers are often tested to identify […]
The advancement of sequencing technology has had the singe biggest effect on genomics research. As it develops further, so does the scope of genomic research and applications.
The Digital DNA series will explore the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. In the first of our Digital DNA series, we talked to Dr. Peter Ney, a researcher in the […]
Although it has been known that different genes determine different characteristics in male and females, new research suggests that differences in gene expression has a much larger impact than previously thought. Many diseases and traits show difference between the sexes. For example, autism is more common in males than females, but multiple sclerosis is more […]
Intermountain Healthcare and deCODE Genetics, a subsidiary of Amgen based in Iceland, have announced a major joint collaboration and study of 500,000 genomes centred around discovering new connections between genetics and human diseases. The study represents the largest US DNA-mapping attempt from a single population.
Advancements in sequencing technology and per sample cost reductions are driving rapid adoption of NGS by labs all over the world. Complementary software solutions are a critical enabler for raw data processing and biological discovery, and new cloud-based platforms provide scalability and ease of use. In this webinar, learn how IBM Aspera and BlueBee offer […]
Dr Ben Langmead is a computational biologist and assistant professor in the Computer Science Department at Johns Hopkins University, most famous for his creation of the Bowtie and Bowtie 2 sequence alignment algorithms, used to improve sequencing alignment quality. FLG spoke to Dr Langmead about his lab, his recent work using the Stampede2 supercomputer cluster to optimise sequencing data analysis software, and the future for DNA sequencers as a whole.
Front Line Genomics’ “Biodata Analysis and Management – Genome Analytics, Interoperability, and Data Life Cycle” report isn’t just an update of our old Genomic Data 101 guides: packed with new information on AI and machine learning,. data discoverability and data interoperability, it is much much more.
Oncology and precision medicine company Strata Oncology has announced the launch of its expanded StrataNGS test 3.0 for patients with advanced cancer. The test analyses 500 genes for three particular immunotherapy biomarkers, microsatellite instability (MSI), tumor mutational burden (TMB) and PD-L1, to better inform use of precision treatments.
Oxford Nanopore has made its Flongle starter packs available to purchase, following an early-access testing programme. The Flongle machine allows for smaller, on-demand DNA sequence testing at low cost.
Oxford Nanopore has launched its two new “109” cDNA kits, which provide high throughput while generating complete sequences of full-length cDNA strands with a low input option of just 1ng PolyA+ RNA.
Genomics England has announced the appointment of Jonathan Symonds CBE as its new Chair to replace Sir John Chisholm, who leaves the organisation on 29 January 2019. Genomics England’s CEO, Professor John Mattick, is also stepping down to be temporarily replaced by Genomic England’s current Chief Scientist, Professor Mark Caulfield.
The first results of the BabySeq Project, a study to determine whether deep dives into infant DNA could uncover more diseases, and whether making this procedure routine after childbirth would be worth it, have been published.
Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!
A new technology known as “Pattern to Knowledge” (P2K) has been created by researchers at the University of Waterloo to predict the binding of biosequences in only seconds. The new development could radically speed up discovery of new drugs and reduce the need for expensive laboratory tests.